ColoPro is positioned for US market entry via the Laboratory Developed Test pathway, with a two-tranche capital raise funding operations through to first revenue.
Same pathway used by Exact Sciences, Guardant Health, and Foundation Medicine. Fastest, most capital-efficient route to clinical traction and M&A positioning.
CDA signed. Proteomics platform and preliminary APL data shared.
Met Senior VP and Head of BD. Formal process initiated.
Material Transfer Agreement, a critical cross-platform validation step.
Partner being acquired by major global diagnostics corp.
Complementary, not competing: we work with whole blood; they work with plasma. The MTA validates ColoPro across sample types. Our whole blood platform remains a distinct proprietary advantage.
Real-world evidence and revenue ahead of regulatory. 12-18 months to first revenue.
Real-world uptake is the most compelling commercial signal for any acquirer.
Reimbursement via procedure codes, payer agreements. Not just IP.
Acquirers pay a premium. Higher valuation, stronger negotiating position.
Pre-money: US$14.3M (A$22M)
US Series B Diagnostics Median: $157M
| Deal | Price | Stage | Revenue | Multiple | Note |
|---|---|---|---|---|---|
| Qiagen → Verogen | $150M | Early commercial | ~$20M | ~7.5× | Best comp ★ |
| Sonic → Diagnosticum | ~$207M | Mature profitable | ~$70M | ~3.2× | Revenue floor |
| Quest → Haystack | $300M+ | Pre-revenue | ~$0 | Pure IP | Tech premium |
